UNSPSC 51453015: Piperazine phosphate

This classification denotes an antihelminthic agent with the molecular formula C4H10N2.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8TIF7T48FP, chemically known as piperazine, phosphate but more generally known as piperazine phosphate, which bears US NIH Compound Identifier 64733. European Medicines Agency schedules Piperazine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14888MIG.

Most nations, for tariff and trade purposes, schedule piperazine phosphate under HS 29335990 and SITC 51576. As of Q4 2014, PIPERAZINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Piperazine phosphate bears US NLM identifiers UMLS ID C0137095 and NCI Concept Code C76724. SMILES: C1CNCCN1.O.OP(=O)(O)O.

UNSPSC 51453015 Piperazine phosphate, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The source contains four recent opportunities tagged under this code, but only one—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—involves pharmaceutical products directly related to the code's chemical category. The other three solicitations (Tampa Fire Department medical and first aid supplies, Minnesota MMCAP generic pharmaceuticals and OTC products, and Texas HHS Request for Information on direct-to-manufacturer prescriptions) address broader pharmaceutical and medical supply procurement but do not target piperazine phosphate specifically. State and local governments using this code are primarily health departments, county health systems, and cooperative purchasing alliances serving multi-state public health and public safety agencies, rather than specialized pharmaceutical manufacturers or chemical distributors.

Recent activity is limited geographically to Florida, Texas, and Minnesota, with the most concrete opportunity being Seminole County's competitive bid for 1,900 annual units of naloxone and 800 drug deactivation systems, due July 26, 2023, with quarterly deliveries required to Sanford, Florida and a two-year initial term plus one-year renewal option. The mismatch between the code's chemical name and the actual procurement substance (naloxone and harm-reduction supplies rather than piperazine phosphate) suggests either miscategorization in the state and local system or use of this code as a fallback catch-all for pharmaceutical and medical chemistry products. Business development professionals should verify category alignment with individual issuing bodies before pursuing opportunities under this code, as the code appears to capture a diverse set of pharmaceutical, medical supply, and OTC product procurements rather than a coherent market segment around piperazine phosphate itself.